WallStSmart

CapsoVision, Inc. Common Stock (CV)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 186216% more annual revenue ($25.27B vs $13.56M). SYK leads profitability with a 13.2% profit margin vs -198.9%. SYK earns a higher WallStSmart Score of 55/100 (C-).

CV

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -13.46

SYK

Buy

55

out of 100

Grade: C-

Growth: 6.0Profit: 6.5Value: 3.3Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CV.

SYKSignificantly Overvalued (-49.0%)

Margin of Safety

-49.0%

Fair Value

$223.22

Current Price

$332.71

$109.49 premium

UndervaluedFair: $223.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CV1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$127.55B9/10

Large-cap with strong market position

Areas to Watch

CV4 concerns · Avg: 3.8/10
Price/BookValuation
18.3x4/10

Trading at 18.3x book value

Revenue GrowthGrowth
0.3%4/10

0.3% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$375.73M3/10

Smaller company, higher risk/reward

SYK4 concerns · Avg: 3.8/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

P/E RatioValuation
38.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CV

The strongest argument for CV centers on Debt/Equity.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap.

Bear Case : CV

The primary concerns for CV are Price/Book, Revenue Growth, EPS Growth.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

CV profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

SYK is growing revenue faster at 2.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (55/100 vs 14/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CapsoVision, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?